Shares of Ampio Pharmaceuticals, Inc. (NYSE:AMPE) recorded -7.00% loss during trading session on December 4th, 2018. The script traded as low as $0.62 and last traded at $0.65. 5.42 million shares changed exchanged hands during trading, a drop of -264.05% from the 30-day average session volume of 1.49M shares. The firm had previously closed at $0.70. The company has $108.33M outstanding shares, price-to-earnings-growth ratio of and a beta of 0.00. The company has a RSI of 58.15, ATR of 0.07 and a volatility of 11.66% this week. AMPE has a 52 week low price of $0.35 and a 52 week high price of $4.95.

Investors have identified the tech company Ampio Pharmaceuticals, Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 70.43M, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Ampio Pharmaceuticals, Inc. (AMPE) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For AMPE, the company has in raw cash 8.67 million on their books with 0 currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 6.36 million total, with 15.57 million as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.

AMPE were able to record 0 as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 0. In cash movements, the company had a total of 0 as operating cash flow.

Potential earnings growth for Ampio Pharmaceuticals, Inc. (AMPE)

In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Ampio Pharmaceuticals, Inc. recorded a total of 1.94 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -0.58% coming in sequential stages and their sales for the third quarter reducing by -0.61%.

What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 1.94 million trying to sell their products during the last quarter, with the result yielding a gross income of 3000. This allows shareholders to hold on to 108.33M with the revenue now reading 0 cents per share.